Annals of Oncology 14:197-204, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
1 The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam; 2 The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, The Netherlands; 3 Universitätsklinikum Charité der Humboldt, Berlin University, Berlin, Germany; 4 Ashford Cancer Center, Ashford, Australia; 5 Daniel den Hoed Kliniek, Rotterdam, The Netherlands; 6 Algemeen Ziekenhuis Stuyvenberg, Antwerpen, Belgium; 7 IVAX Research Inc., Miami, FL, USA
Received 25 June 2002; revised 21 October 2002; accepted 7 November 2002
Background:
Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel. Two doses of oral paclitaxel on 1 day in combination with CsA resulted in higher systemic exposure than single dose administration.
Patients and methods:
In this phase II study, chemonaïve patients with advanced gastric cancer received oral paclitaxel weekly in two doses of 90 mg/m2 on the same day; CsA (10 mg/kg) was given 30 min before each dose of oral paclitaxel.
Results:
In 25 patients, the main toxicities were: nausea CTC grade 2/3, 10 patients (40%); vomiting grade 2/3, 4 patients (20%); diarrhea grade 2/3, 6 patients (24%); neutropenia grade 3/4, 5 patients (20%). In the 24 evaluable patients, eight partial responses were observed, resulting in an overall response rate (ORR) of 33% [95% confidence interval (CI) 18% to 52%]. Eleven patients had stable disease (46%) and 5 patients showed progressive disease (21%). The ORR in the total population was 32% (95% CI 17% to 50%). The median time to progression was 16 weeks (95% CI 9–22). Pharmacokinetic analyses revealed that the mean area under the plasma concentration–time curve (AUC) of orally administered paclitaxel (± standard deviation) was 3757.6 ± 939.4 ng·h/ml in week 1 and 3928.4 ± 1281 ng·h/ml in week 2. The intrapatient variability in the AUC was 12%.
Conclusions:
Oral paclitaxel in combination with CsA is both active and safe in chemonaïve patients with advanced gastric cancer. Toxicities were mainly gastrointestinal.
Key words: advanced gastric cancer, chemotherapy, cyclosporin A, paclitaxel, toxicity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. De Giorgi, G. Rosti, M. Monti, G. L. Frassineti, and M. Marangolo Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL) Ann. Onc., October 1, 2003; 14(10): 1588 - 1589. [Full Text] [PDF]
|
|
|
|
|
|
G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth Chemotherapy in gastric cancer: a never ending saga Ann. Onc., February 1, 2003; 14(2): 175 - 177. [Full Text] [PDF]
|
|